Garvan Institute

The Australian Pancreatic Cancer Genome


The Australian Pancreatic Cancer Genome


2015 Accelerator Grant



Principal Investigator

Dr Anthony Gill, Honorary Clinical Fellow - Garvan Institute of Medical Research and The Kinghorn Cancer Centre and Chairman-Elect of the Australian Pancreatic Cancer Genome Initiative

Time required to complete project

3 years

Project Summary

The APGI's ongoing mission is to further develop the existing world-class resource comprising biological samples and comprehensive information on pancreatic cancer patients from diagnosis onwards, including clinical, genomic and outcome data and to use this resource to improve pancreatic cancer care in the era of personalised medicine. Biospecimens are materials taken from the human body, such as tissue or blood, that can be used for cancer diagnosis and analysis. When patients have a biopsy or surgery often a small amount of the specimen removed can be stored and used for research. Biospecimens contain an extraordinary amount of biological information, written in the language of cells, genes and proteins. Researchers can then frame questions that will be answered by looking at these biospecimens, for example, they often use the biospecimen to identify the biological characteristics of cancer cells over time, and then correlate those patterns with the clinical picture ­ - and investigate how different patients experience progression of the disease.

Dr Anthony Gill, APGI

Research Reports
Click to download progress reporting on the outcomes of this research.

Progress Report